Get access

Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A

Authors


Dr. Kathleen E. Brummel-Ziedins, University of Vermont, Department of Biochemistry, 208 South Park Drive, Suite 2, Colchester VT 05446, USA.
Tel.: +802 656 9599; fax: +802 656 2256;
e-mail: Kathleen.brummel@uvm.edu

Abstract

Summary.  Individuals with haemophilia A exhibit bleeding tendencies that are not always predicted by their factor (F)VIII level. It has been suggested that bleeding in haemophilia is due not only to defective prothrombin activation but also aberrant fibrinolysis. Thrombin activatable fibrinolysis inhibitor (TAFI) activation was measured in tissue factor (TF)-initiated blood coagulation in blood samples of 28 haemophiliacs and five controls. Reactions were quenched over time with FPRck and citrate and assayed for TAFIa and thrombin-antithrombin (TAT). The TAFIa potential (TP), TAFI activation rate and the TAFIa level at 20 min (TAFIa20 min) was extracted from the TAFI activation progress curve. In general, the time course of TAFI activation follows thrombin generation regardless of FVIII activity and as expected the rate of TAFI activation and TP decreases as FVIII decreases. The magnitude of TP was similar among the control subjects and subjects with <11% FVIII. In severe subjects with <1% FVIII at the time of blood collection, the TAFIa20 min was inversely and significantly correlated with haemarthrosis (−0.77, = 0.03) and total bleeds (−0.75, = 0.03). In all cases, TAFIa20 min was more strongly correlated with bleeding than TAT levels at 20 min. Overall, this study shows that TAFI activation in whole blood can be quantified and related to the clinical bleeding phenotype. Measuring TAFIa along with thrombin generation can potentially be useful to evaluate the differential bleeding phenotype in haemophilia A.

Ancillary